Indiana University School Of Medicine

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1903-01-01

Employees: -

Market Cap: -

Website: http://www.medicine.iu.edu

Clinical Trials

Aripiprazole Treatment of Bipolar Depression

Phase 4

Completed

Conditions: Bipolar Depression

First Posted Date: 2005-09-20

Last Posted Date: 2007-04-05

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 10

Registration Number: NCT00198198

Locations: 🇺🇸
UH 3124 University Hospital, Indianapolis, Indiana, United States

A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR

Phase 2

Terminated

Conditions: Refractory Germ Cell Tumors Expressing EGRF

First Posted Date: 2005-09-20

Last Posted Date: 2014-09-19

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 21

Registration Number: NCT00198159

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.

Phase 2

Completed

Conditions: Pervasive Developmental Disorder
Asperger's Disorder

Interventions: Drug: aripiprazole

First Posted Date: 2005-09-20

Last Posted Date: 2014-06-04

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 25

Registration Number: NCT00198055

Locations: 🇺🇸
Riley Hospital, Riley Child and Adolescent Psychiatry Clinic, Indianapolis, Indiana, United States

Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors

Phase 2

Terminated

Conditions: Germ Cell Tumor

First Posted Date: 2005-09-20

Last Posted Date: 2014-06-03

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 37

Registration Number: NCT00198172

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2005-09-20

Last Posted Date: 2014-06-03

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 40

Registration Number: NCT00198237

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients

Not Applicable

Completed

Conditions: Renal Failure

First Posted Date: 2005-09-20

Last Posted Date: 2005-09-20

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 50

Registration Number: NCT00198224

Locations: 🇺🇸
University Hospital, Indianapolis, Indiana, United States
🇺🇸
Indiana University Hospital and Emerson Hall, Indiana University School of Medicine, Indianapolis, Indiana, United States

A Study of Sertraline and Early Alprazolam XR Administration Versus Sertraline Only in Panic Disorder Patients

Phase 4

Completed

Conditions: Panic Disorder

First Posted Date: 2005-09-20

Last Posted Date: 2007-10-22

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 150

Registration Number: NCT00198094

Locations: 🇺🇸
University of Pennsylvania, Mood and Anxiety Disorders Section, Philadelphia, Pennsylvania, United States
🇺🇸
University of South Florida, Department of Psychiatry and Behavioral Medicine, Tampa, Florida, United States
🇺🇸
University Hospital Outpatient Center, Psychiatry, Indianapolis, Indiana, United States

Venlafaxine for Hot Flashes After Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2005-09-20

Last Posted Date: 2008-11-14

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 75

Registration Number: NCT00198250

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

Prevention of Diabetes Progression Trial (PDPT)

Phase 2

Completed

Conditions: Newly Diagnosed With Type 1 Diabetes

First Posted Date: 2005-09-20

Last Posted Date: 2020-08-11

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 40

Registration Number: NCT00198146

Locations: 🇺🇸
Indiana University - Riley Hospital for Children, Indianapolis, Indiana, United States

Bisphosphonate Therapy for Osteogenesis Imperfecta

Phase 4

Completed

Conditions: Osteogenesis Imperfecta
Osteoporosis
Paget Disease of Bone

Interventions: Drug: Pamidronate
Drug: Alendronate

First Posted Date: 2005-09-12

Last Posted Date: 2017-06-14

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 18

Registration Number: NCT00159419

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy